A clinical study of MK-1084 and other treatments for lung cancer (MK-1084-007)

Prior treatment

• Has not adequately recovered from major surgery or has ongoing surgical complications
• Has active inflammatory bowel disease requiring immunosuppressive medication or previous clear history of inflammatory bowel disease (e.g., Crohn’s disease, ulcerative colitis, or chronic diarrhea)
• Has received prior systemic anticancer therapy for their advanced or metastatic NSCLC

Other illness

• Has diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements
• History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
• Has active infection requiring systemic therapy except those specified by protocol
• Has history of stem cell/solid organ transplant
• Has uncontrolled, significant cardiovascular disease or cerebrovascular disease
• Has a gastrointestinal disorder affecting absorption
• Is HIV positive and has a history of Kaposi’s sarcoma and/or Multicentric Castleman’s Disease
• Has known additional malignancy that is progressing or has required active treatment within the past 3 years
• Has active autoimmune disease that has required systemic treatment in the past 2 years

Other

• Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis

• Has nonsquamous non—small cell lung cancer (NSCLC) (Stage IIIB, Stage IIIC) not eligible for curative resection or chemoradiation or Stage IV: M1a, M1b, or M1c
• If human immunodeficiency virus (HIV) positive, must have well controlled HIV on antiretroviral therapy (ART)